Drugs

, Volume 62, Issue 4, pp 577–592

Management of Fibromyalgia

What are the Best Treatment Choices?
Therapy in Practice

Abstract

Fibromyalgia still represents an enigma to modern medicine and the aetiopathogenesis is far from explored. The management of patients with fibromyalgia is thus mostly based on empirical research, and only a few controlled studies have been performed. Basic drug therapy rests on the administration of amitriptyline and conventional analgesics. Such therapy should be initiated only after careful patient information and delineation of therapeutic goals are provided. Any drug therapy should be administered in combination with physical treatment and cognitive behavioural therapy. Because of the appearing contours of pathogenic mechanisms, hopefully a number of new drugs will be available to the patients with this complex pain syndrome in the near future.

References

  1. 1.
    Wolfe F. The clinical syndrome of fibrositis. Am J Med 1986 Sep 29; 81 Suppl. 3A: 7–14PubMedCrossRefGoogle Scholar
  2. 2.
    Yunus M, Masi A, Aldag J. A controlled study of primary fibromyalgia syndrome: clinical features and association with other functional syndromes. JRheumatol 1989 Feb; 16 Suppl. 19: 62–71Google Scholar
  3. 3.
    Wolfe F, Smythe H, Yunus M, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990 Feb; 33(2): 160–72PubMedCrossRefGoogle Scholar
  4. 4.
    Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995 Jan; 38(1): 19–28PubMedCrossRefGoogle Scholar
  5. 5.
    Raspe H, Baumgartner C. The epidemiology of the fibromyalgia syndrome (FMS) in German town [abstract]. Scand J Rheumatol 1992; Suppl. 94: S8Google Scholar
  6. 6.
    Lydell C. The prevalence of fibromyalgia in a south African community [abstract]. Scand J Rheumatol 1992; Suppl. 94: S8Google Scholar
  7. 7.
    Buskila D, Press J, Klein M, et al. Assessment of nonarticular tenderness and prevalence of fibromyalgia in children. J Rheumatol 1993 Feb; 20(2): 368–70PubMedGoogle Scholar
  8. 8.
    Forseth KØ, Gran JT. The prevalence of fibromyalgia among women aged 20–49 years in Arendal, Norway. Scand J Rheumatol 1992; 21(2): 74–8PubMedCrossRefGoogle Scholar
  9. 9.
    Bengtsson A, Henriksson K, Jorfeldt L, et al. Primary fibromyalgia: a clinical and laboratory study of 55 patients. Scand J Rheumatol 1986; 15(3): 340–7PubMedCrossRefGoogle Scholar
  10. 10.
    Cathey MA, Wolfe F, Kleinheksel SM, et al. Functional ability and work status in patients with fibromyalgia. Arthritis Care Res 1988; 1:85–98CrossRefGoogle Scholar
  11. 11.
    Turk D, Rudy T, Stieg R. The disability determination dilemma: toward a multiaxial solution. Pain 1988 Sep; 34(3): 217–29PubMedCrossRefGoogle Scholar
  12. 12.
    McCain G, Cameron R, Kennedy J. The problem of longterm disability payments and litigation in primary fibromyalgia: the Canadian perspective. J Rheumatol 1989 Nov; 16 Suppl. 19: 174–6Google Scholar
  13. 13.
    Henriksson CM. Longterm effects of fibromyalgia on everyday life: a study of 56 patients. Scand J Rheumatol 1994; 23(1): 36–41PubMedCrossRefGoogle Scholar
  14. 14.
    Wolfe F, Aarflot T, Bruusgaard D, et al. Fibromyalgia and disability. Report of the Moss International Working Group on medico-legal aspects of chronic widespread pain complaints and fibromyalgia. Scand J Rheumatol 1995; 24(2): 112–8PubMedCrossRefGoogle Scholar
  15. 15.
    Gjesdahl S, Kristiansen AM. The rise and possible fall of the Norwegian fibromyalgia epidemic: what does insurance statistics show [in Norwegian]. Tidsskr Nor Lægeforen 1997; 117: 249–53Google Scholar
  16. 16.
    Forseth KØ, Gran JT, Husby G. A population study of the incidence of fibromyalgia among women aged 26–55 yr. Br J Rheumatol 1997 Dec; 36(12): 1318–23PubMedCrossRefGoogle Scholar
  17. 17.
    Felson D. Epidemiologic research in fibromyalgia. J Rheumatol 1989 Nov; 16 Suppl. 19:7–11Google Scholar
  18. 18.
    Forslind K, Fredriksson E, Nived O. Does primary fibromyalgia exist? Br J Rheumatol 1990 Oct; 29(5): 368–70PubMedCrossRefGoogle Scholar
  19. 19.
    Brückle W, Lautenschläger J, Müller W. The course and topography of pain in fibromyalgia. EULAR Bulletin 1992; 1:12–8Google Scholar
  20. 20.
    Nørregaard J, Bülow PM, Prescott E, et al. A four-year follow-up study in fibromyalgia: relationship to chronic fatigue syndrome. Scand J Rheumatol 1993; 22(1): 35–8PubMedCrossRefGoogle Scholar
  21. 21.
    Ledingham J, Doherty S, Doherty M. Primary fibromyalgia syndrome: an outcome study. Br J Rheumatol 1993 Feb; 32(2): 139–42PubMedCrossRefGoogle Scholar
  22. 22.
    Bengtsson A, Bäckman E, Lindblom B, et al. Term follow-up of fibromyalgia patients: clinical symptoms, muscular function, laboratory tests: an eight year comparison study. J Musculoskel Pain 1994; 2: 67–79CrossRefGoogle Scholar
  23. 23.
    Granges G, Zilko P, Littlejohn G. Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. J Rheumatol 1994 Mar; 21(3): 523–9PubMedGoogle Scholar
  24. 24.
    Buskila D, Neumann L, Hershman E, et al. Fibromyalgia syndrome in children: an outcome study. J Rheumatol 1995 Mar; 22(3): 525–8PubMedGoogle Scholar
  25. 25.
    Mikkelson M. One year outcome of preadolescents with fibromyalgia. J Rheumatol 1999; 26: 674–82Google Scholar
  26. 26.
    Forseth KØ, Førre Ø, Gran JT. A 5.5 years prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population; significance and natural history. Clin Rheumatol 1999; 18(2): 114–21PubMedCrossRefGoogle Scholar
  27. 27.
    Pellegrino M, Waylonis G, Sommer A. Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 1989; 70: 61–3PubMedGoogle Scholar
  28. 28.
    Buskila D, Neumann L, Hazanov I, et al. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996 Dec; 26(3): 605–11PubMedCrossRefGoogle Scholar
  29. 29.
    Yunus M, Khan M, Rawlings K, et al. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999 Feb; 26(2): 408–12PubMedGoogle Scholar
  30. 30.
    Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999 Oct; 6(5): 433–9PubMedCrossRefGoogle Scholar
  31. 31.
    Hudson J, Pope H. Fibromyalgia and psychopathology: is fibromyalgia a form of ’affective spectrum disorder’? J Rheumatol 1989 Nov; 16 Suppl. 19: 15–22Google Scholar
  32. 32.
    Bennett R. Confounding features of the fibromyalgia syndrome: a current perspective of differential diagnosis. J Rheumatol 1989 Nov; 16 Suppl. 19: 58–61Google Scholar
  33. 33.
    Bennett R. Physical fitness and muscle metabolism in the fibromyalgia syndrome: an overview. J Rheumatol 1989 Nov; 16 Suppl. 19: 28–9Google Scholar
  34. 34.
    Pongratz DE. Zur Myopathologie der generalisierten ten-domyopathie. In: Müller W, editor. Generalisierte ten-domyopathie. Darmstadt: Steinkopff, 1991: 145–52Google Scholar
  35. 35.
    Bengtsson A, Henriksson K. The muscle in fibromyalgia: a review of Swedish studies. J Rheumatol 1989 Nov; 16 Suppl. 19: 144–9Google Scholar
  36. 36.
    Drewes A, Andreasen A, Schrøder HD, et al. Pathology of skeletal muscle in fibromyalgia: a histo-immuno-chemical and ultrastructural study. Br J Rheumatol 1993 Jun; 32(6): 479–83PubMedCrossRefGoogle Scholar
  37. 37.
    Smythe H. ‘Fibrositis’ as a disorder of pain modulation. Clin Rheum Dis 1979; 5: 823–32Google Scholar
  38. 38.
    Smythe H. Tender points: evolution of concepts of the fibrositis/fibromyalgia syndrome. Am J Med 1986 Sep; 81 Suppl. 3A: 2–6PubMedCrossRefGoogle Scholar
  39. 39.
    Smythe H. Fibrositis syndrome: a historical perspective. J Rheumatol 1989 Nov; 16 Suppl 19: 2–6Google Scholar
  40. 40.
    Yunus M. Towards a model of pathophysiology of fibromyalgia: abberant central pain mechanisms with peripheral modulation. J Rheumatol 1992 Jun; 19(6): 846–9PubMedGoogle Scholar
  41. 41.
    Henriksson K, Mense S. Pain a nociception in fibromyalgia: clinical and neurobio-logical considerations on aetiology and pathogenesis. Pain Rev 1994; 1: 245–60Google Scholar
  42. 42.
    Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 1998 Jun; 315(6): 377–85PubMedCrossRefGoogle Scholar
  43. 43.
    Vasrøy H, Helle R, Førre ø, et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988 Jan; 32(1): 21–6CrossRefGoogle Scholar
  44. 44.
    Russell IJ. Pathogenesis of fibromyalgia: the neurohormonal hypothesis. J Musculoskel Pain 1994; 2: 73–86CrossRefGoogle Scholar
  45. 45.
    Bradley LA, Alberts KR, Alarcon GS. Abnormal brain regional cerebral flow (rCBF) and cerebrspinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM) [abstract]. Arthritis Rheum 1996; 39 Suppl. 9: S212Google Scholar
  46. 46.
    Russell IJ. Neurochemical pathogenesis of fibromyalgia syndrome. J Musculoskel Pain 1996; 4: 61–92CrossRefGoogle Scholar
  47. 47.
    Larson AA, Giovengo SL, Russell IJ, et al. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000 Aug; 87(2): 201–11PubMedCrossRefGoogle Scholar
  48. 48.
    Willis WD. The pain system: the neural basis of nociceptive transmission in the mammalian nervous system. Basel: Karger, 1985Google Scholar
  49. 49.
    Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986; 81 Suppl 3A: 85–9PubMedCrossRefGoogle Scholar
  50. 50.
    Moldofsky H. Sleep and fibrosis syndrome. Rheum Dis Clin North Am 1989 Feb; 15(1): 91–100PubMedGoogle Scholar
  51. 51.
    Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol 2000; 29 Suppl. 113: 8–12CrossRefGoogle Scholar
  52. 52.
    Wolfe F, Cathey M, Kleinheksel S. Fibrositis (fibromyalgia) in rheumatoid arthritis. J Rheumatol 1984 Dec; 11(6): 814–8PubMedGoogle Scholar
  53. 53.
    Bonafede RP, Downey C, Bennett R. An association of fibromyalgia with primary Sjögren’s Syndrome: a prospective study of 72 patients. J Rheumatol 1995 Jan; 22(1): 133–6PubMedGoogle Scholar
  54. 54.
    Wallace D, Romano T. Prevalence of fibromyalgia in systemic lupus erythematosus patients: comment on the article by Middleton, et al. Arthritis Rheum 1995 Jun; 38(6): 872PubMedCrossRefGoogle Scholar
  55. 55.
    Cimmino M, Parisi M, Moggiana G, et al. The association between fibromyalgia and carpal tunnel syndrome in the population [abstract]. Ann Rheum Dis 1996 Oct; 55(10): 780PubMedCrossRefGoogle Scholar
  56. 56.
    Bennett RM, Clark SR, Goldberg L, et al. Aerobics fitness in patients with fibrositis. A controlled study of respiratory gaz exchange nd 133 xenon clearance from exercising muscle. Arthritis Rheum 1989 Apr; 32(4): 454–60PubMedCrossRefGoogle Scholar
  57. 57.
    Clark S, Burkhardt CS, Campbell S. Fitness characteristics and perceived exertion in women with fibromyalgia. J Musculoskel Pain 1993; 1: 193–7CrossRefGoogle Scholar
  58. 58.
    McCain G, Bell D, Mai F, et al. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988 Sep; 31(9): 1135–41PubMedCrossRefGoogle Scholar
  59. 59.
    Wigers S, Stiles T, Vogel PA. Effects of aerobic exercise versus stress management treatment in fibromyalgia: a 4.5 year prospective study. Scand J Rheumatol 1996; 25(2): 77–86PubMedCrossRefGoogle Scholar
  60. 60.
    Martin L, Nutting A, Macintosh BR, et al. An exercise program in the treatment of fibromyalgia. J Rheumatol 1996 Jun; 23(6): 1050–3PubMedGoogle Scholar
  61. 61.
    Nichols D, Glenn DS. Effects of aerobic exercise on pain perception, affect, and level of disability in individuals with fibromyalgia. Phys Ther 1994 Apr; 74(4): 327–32PubMedGoogle Scholar
  62. 62.
    Verstappen FTJ, van Santen-Hoefft HMS, Bolwijn PH, et al. Effects of a group activity program for fibromyalgia patients on physical fitness and well being. J Musculoskel Pain 1997; 5: 17–28CrossRefGoogle Scholar
  63. 63.
    Mengshoel AM, Førre Ø. Physical fitness training in patients with fibromyalgia. J Musculoskel Pain 1993; 1: 267–72CrossRefGoogle Scholar
  64. 64.
    Wigers SH. Fibromyalgia outcome: the predictive values of symptom duration, physical activity, disability pension, and critical life events: a 4.5 year study. J Psychosom Res 1996 Sep; 41(3): 235–43PubMedCrossRefGoogle Scholar
  65. 65.
    Minor MA, Sanford MK. The role of physical therapy and physical modalities in pain management. Rheum Dis Clin North Am 1999 Feb; 25(1): 233–48PubMedCrossRefGoogle Scholar
  66. 66.
    Melzack R, Wall PD. Pain mechanism: a new theory. Science 1965 Nov; 150(699): 971–9PubMedCrossRefGoogle Scholar
  67. 67.
    Justins DM. Management strategies for chronic pain. Ann Rheum Dis 1996 Sep; 55(9): 588–96PubMedCrossRefGoogle Scholar
  68. 68.
    Johnson MI, Ashton CH, Thompson JW. An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS): implications for clinical use of TENS. Pain 1991 Mar; 44(3): 221–9PubMedCrossRefGoogle Scholar
  69. 69.
    Berman B, Ezzo J, Hadhazy V, et al. Is acupuncture effective in the treatment of fibromyalgia? J Fam Pract 1999 Mar; 48(3): 213–8PubMedGoogle Scholar
  70. 70.
    Deluze C, Bosia 1, Zirbs A, et al. Electroacupuncture in fibromyalgia: results of a controlled trial. BMJ 1992 Nov 21; 305(6864): 1249–52PubMedCrossRefGoogle Scholar
  71. 71.
    Ferraccioli G, Ghirelli L, Scita F, et al. EMG-biofeedback training in fibromyalgia syndrome. J Rheumatol 1987 Aug; 14(4): 820–5PubMedGoogle Scholar
  72. 72.
    Buckelew SP, Conway R, Parker J, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. Arthritis Care Res 1998 Jun; 11(3): 196–209PubMedCrossRefGoogle Scholar
  73. 73.
    Bradley L. Cognitive-behavioral therapy for primary fibromyalgia. J Rheumatol 1989; 16 Suppl. 19: 131–6Google Scholar
  74. 74.
    Morley S, Eccleston C, Wiliams A. Systematic review and meta-analyses of randomized controlled trials of cognitive behaviour therapy and behavioural therapy for chronic pain in adults, excluding headache. Pain 1999 Mar; 80(1–2): 1–13PubMedCrossRefGoogle Scholar
  75. 75.
    Sandström MJ, Keefe FJ. Self-management of fibromyalgia: the role of formal coping skills training anf physical exercise training programs. Arthritis Care Res 1998 Dec; 11(6): 432–47PubMedCrossRefGoogle Scholar
  76. 76.
    Lautenschläger J. Present state of medication therapy in fibromyalgia syndrome. Scand J Rheumatol 2000; 29 Suppl. 113: 32–6CrossRefGoogle Scholar
  77. 77.
    Goldenberg D, Felson D, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986 Nov; 29(11): 1371–7PubMedCrossRefGoogle Scholar
  78. 78.
    Yunus M, Masi A, Aldag J. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double-blind, placebo controlled trial. J Rheumatol 1989 Apr; 16(4): 527–32PubMedGoogle Scholar
  79. 79.
    Russell IJ, Fletcher E, Michalek JE, et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study. Arthritis Rheum 1991 May; 34(5): 552–60PubMedCrossRefGoogle Scholar
  80. 80.
    Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 1996 May–Jun; 65(2-3): 221–5PubMedCrossRefGoogle Scholar
  81. 81.
    Værøy H, Abrahamsen A, Førre Ø, et al. Treatment of fibromyalgia (Fibrositis syndrome): a parallel double-blind trial with carioprodol, paracetamol and caffeïne (Somadril comp) versus placebo. Clin Rheumatol 1989 Jun; 8(2): 245–50PubMedCrossRefGoogle Scholar
  82. 82.
    Wolfe F, Zhao S, Lane N. Preference for nonsteroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000 Feb; 43(2): 378–85PubMedCrossRefGoogle Scholar
  83. 83.
    Biasi G, Manca S, Manganelli S, et al. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998; 18(1): 13–9PubMedGoogle Scholar
  84. 84.
    Russell IJ. Kamin M, Bennett RM, et al. Efficacy of tramadol in treatment of pain in fibromyalgia. Clin Rheumatol 2000; 6(5): 250–7CrossRefGoogle Scholar
  85. 85.
    Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum1988 Dec; 31(12): 1535–42PubMedCrossRefGoogle Scholar
  86. 86.
    Quimby LG, Gratwiick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 1989 Nov; 16 Suppl. 19: 140–3Google Scholar
  87. 87.
    Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991 Mar; 18: 452–4PubMedGoogle Scholar
  88. 88.
    Carette S, Bell M, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. Arthritis Rheum 1994 Jan; 37(1): 32–40PubMedCrossRefGoogle Scholar
  89. 89.
    Drewes A, Andreasen A, Jennum P, et al. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 1991; 20(4): 288–93PubMedCrossRefGoogle Scholar
  90. 90.
    Grönblad M, Nykänen J, Konttinen Y, et al. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients: a double-blind randomized trial. Clin Rheumatol 1993 Jun; 12(2): 186–91PubMedCrossRefGoogle Scholar
  91. 91.
    Moldofsky H, Lue F, Mously C, et al. The effect of zolpidem in patients with FM: a dose ranging, double-blind, placebo controlled, modified crossover study. J Rheumatol 1996 Mar; 23(3): 529–33PubMedGoogle Scholar
  92. 92.
    Clark S, Tindall E, Bennett R. A double crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985 Oct; 12(5): 980–3PubMedGoogle Scholar
  93. 93.
    Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998 Dec; 37(12): 1279–86PubMedCrossRefGoogle Scholar
  94. 94.
    Wolfe F, Cathey M, Hawley D. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23(5): 255–9PubMedCrossRefGoogle Scholar
  95. 95.
    Nörregaard J, Volkmann H, Danneskiöld-Samsöe B. Arandomized controlled trial of citalopram inn the treatment of fibromyalgia. Pain 1995 Jun; 61(3): 445–9PubMedCrossRefGoogle Scholar
  96. 96.
    Cantini F, Bellandi F, Niccolo L, et al. Fluoxetine combined with cyclobenzaprine in the treatment of fibromyalgia [in Italian]. Minerva Med 1994 Mar; 85(3): 97–100PubMedGoogle Scholar
  97. 97.
    Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996 Nov; 39(11): 1852–9PubMedCrossRefGoogle Scholar
  98. 98.
    Andenberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Eur J Pain 2000; 4(1): 27–35CrossRefGoogle Scholar
  99. 99.
    Celiker R. Comparison of amitriptyline and sertraline in the treatment of fibromyalgia [abstract]. Arthrit Rheum 2000 Sep; 43 Suppl. 9: S332Google Scholar
  100. 100.
    Carette S, McCain G, Bell D, et al. Evaluation of amitriptyline in primary fibrositis a double-blind, placebo-controlled study. Arthritis Rheum 1986 May; 29(5): 655–9PubMedCrossRefGoogle Scholar
  101. 101.
    Scudds R, McCain G, Rollman G, et al. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol 1989 Nov; 16 Suppl. 19: 98–103Google Scholar
  102. 102.
    Jaeschke R, Adachi J, Guyatt G, et al. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991 Mar; 18(3): 447–51PubMedGoogle Scholar
  103. 103.
    Hong CZ. Lidocaine injection versus dry needling to myofascial trigger point. Am J Phys Med Rehabil 1994 Jul–Aug; 73(4): 256–63PubMedCrossRefGoogle Scholar
  104. 104.
    Hong CZ, Hsueh TC. Difference in pain relief after triggerpoint injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 1996 Nov; 77(11): 1161–6PubMedCrossRefGoogle Scholar
  105. 105.
    Borg-Stein J, Stein J. Triggerpoints and tenderpoints: one and the same? Does injection treatment help? Rheum Dis Clin North Am 1996 May; 22(2): 305–22PubMedCrossRefGoogle Scholar
  106. 106.
    Lofland JH, Szarlej D, Buttaro T, et al. Cyclobenzaprine hydrochloride is a commonly prescribed centrally acting muscle relaxant, which is structurally similar to tricyclic antidepressants (TCAs) and differs from amitriptyline by only one double bond. Clin J Pain 2001 Mar; 17(1): 103–4PubMedCrossRefGoogle Scholar
  107. 107.
    Travell JG, Simmons DG. Myofascial pain and dysfunction. The triggerpoint manual. Baltimore: Williams and Wilkins, 1983Google Scholar
  108. 108.
    Hansen H. Treatment of chronic pain with antiepileptic drugs: a new era. South Med J 1999 Jul; 92(7): 642–9PubMedCrossRefGoogle Scholar
  109. 109.
    Besette L, Carette S, Fossel A, et al. A randomized, double-blind, placebo-controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol 1998 (2); 27: 112–26CrossRefGoogle Scholar
  110. 110.
    Jacobsen S, Danneskiold-Samsøe B, Bach Andersen R. Oral S-adenosylmethionine in primary fibromyalgia: double-blind clinical evaluation. Scand J Rheumatol 1991; 20(4): 294–302PubMedCrossRefGoogle Scholar
  111. 111.
    Volkmann H, Nørregaard J, Jacobsen S, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol 1997; 26(3): 206–11PubMedCrossRefGoogle Scholar
  112. 112.
    Caruso I, Puttini PS, Cazzola M, et al. Double-blind study of %-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990 May; 18(3): 201–9PubMedGoogle Scholar
  113. 113.
    Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992 Apr; 20(2): 182–9Google Scholar
  114. 114.
    Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 1997; 4 Suppl 2: S71–3Google Scholar
  115. 115.
    McCarty DJ, Csuka M, McCarthy G, et al. Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 1994; 23(6): Suppl. 3: 41–7CrossRefGoogle Scholar
  116. 116.
    Scharf M, Hauck M, Stover R, et al. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia: preliminary report. J Rheumatol 1998 Oct; 25(10): 1986–90PubMedGoogle Scholar
  117. 117.
    Bennett RM, Clark SC, Walczyk J. Arandomized, double-blind, placebo-controlled study of growth hormone in the treatment of patients with fibromyalgia. Am J Med 1998 Mar; 104(3): 227–31PubMedCrossRefGoogle Scholar
  118. 118.
    McMahon S, Bennett DL, Priestley JV, et al. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med 1995 Aug; 1(8): 774–80PubMedCrossRefGoogle Scholar
  119. 119.
    Holman Renton AJ. Safety and efficacy of the dopamine agonist, pramipexole, on pain score for refractory fibromyalgia [abstract]. Arthritis Rheum 2000 Sep; 43 Suppl. 9: S333Google Scholar
  120. 120.
    Abraham GE, Flechas JD. Management of fibromyalgia: rationale for the use of magnesium and malic acid. J Nutr Med 1992; 3: 49–59CrossRefGoogle Scholar
  121. 121.
    Sørensen J, Bengtsson A, Backman E, et al. A pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995; 24(6): 360–5PubMedCrossRefGoogle Scholar
  122. 122.
    Øye I, Rabben T, Fagerlund TH. Analgesic effect of ketamine in a patient with neuropathic pain [in Norwegian]. Tidsskr Nor Lægeforen 1996 Okt; 116(26): 3130–1PubMedGoogle Scholar
  123. 123.
    Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000 Apr; 85(3): 483–91PubMedCrossRefGoogle Scholar
  124. 124.
    Haines D, Gaines S. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 1999 Nov; 83(2): 283–7PubMedCrossRefGoogle Scholar
  125. 125.
    Clark SR, Bennett RM. Supplemental dextromethorphan in the treatment of fibromyalgia: a double-blind, placebo-controlled study of efficacy and side-effects [abstract]. Arthritis Rheum 2000 Sep; 43 Suppl. 9: S333Google Scholar
  126. 126.
    Höcherl K, Färber L, Ladenburger S, et al. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia. Scand J Rheumatol 2000; 29 Suppl. 113: 46–8Google Scholar
  127. 127.
    Färber L, Stratz T, Brückle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia — a highly selective and competitive 5-HT3 receptor antagonist. Scand J Rheumatol 2000; 29 Suppl. 113: 49–54CrossRefGoogle Scholar
  128. 128.
    Haus U, Boglarka V, Stratz T, et al. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000; 29 Suppl. 113: 55–8CrossRefGoogle Scholar
  129. 129.
    Müller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol 2000; 29 Suppl. 113:59–62CrossRefGoogle Scholar
  130. 130.
    Birdsall TC. 5-hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998 Aug; 3(4): 271–80PubMedGoogle Scholar
  131. 131.
    Brin MF. Botulinum toxin: new and expanded indications. Eur J Neurol 1997; 4 Suppl. 2: S59–65Google Scholar
  132. 132.
    Holzer P. Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Am Soc Pharmacol Exp Ther 1991;43: 143–201Google Scholar
  133. 133.
    Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999 Jul; 26(7): 1564–9PubMedGoogle Scholar
  134. 134.
    Hewitt DJ. The Use of NMDA-receptor Antagonists in the treatment of Chronic Pain. Clin J Pain 2000 Jun; 16 Suppl. 2: S73–9PubMedCrossRefGoogle Scholar
  135. 135.
    Max MB, Byas-Smith MG, Gracely RH, et al. Intravenous infusoion of the NMDA antagonist, ketamine, in chronic post-traumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995 Aug; 18(4): 360–8PubMedCrossRefGoogle Scholar
  136. 136.
    Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997 May; 48(5): 1212–8PubMedCrossRefGoogle Scholar
  137. 137.
    Eide K, Stubhaug A, øye I, et al. Continuous subcutaneous administration of the N-methyl-D-aspartatic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995 May; 61(2): 221–8PubMedCrossRefGoogle Scholar
  138. 138.
    Nikolajsen L, Hansen CL, Nielsen J, et al. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996 Sep; 67(1): 69–77PubMedCrossRefGoogle Scholar
  139. 139.
    Felsby S, Nielsen J, Arendt-Nielsen L, et al. NMDA rceptor blockade in chronic nuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1996 Feb; 64(2): 283–91PubMedCrossRefGoogle Scholar
  140. 140.
    Eide K, Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-D-aspartate receptor blockade. Neurosurgery 1997; 41: 505–8PubMedCrossRefGoogle Scholar
  141. 141.
    Pud D, Eisenberg E, Spitzer A, et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998 Apr; 75(2–3): 349–54PubMedCrossRefGoogle Scholar
  142. 142.
    Kinnman E, Nygards EB, Hansson P. Effects of dextromethorphan in clinical doses on capsaicin-induced ongoing pain and mechanical hypersensitivity. J Pain Symptom Manage 1997 Oct; 14(4): 195–201PubMedCrossRefGoogle Scholar
  143. 143.
    McQuay HJ, Carroll D, Jadad AR, et al. Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994 Oct; 59(1): 127–33PubMedCrossRefGoogle Scholar
  144. 144.
    Mercadante S, Casuccio A, Genovese G. Ineffectiveness of dextromethorphan in cancer pain. J Pain Symptom Manage 1998 Nov; 16(5): 317–22PubMedCrossRefGoogle Scholar
  145. 145.
    Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol 2000; 29 Suppl. 113: 37–45CrossRefGoogle Scholar
  146. 146.
    GlaxoSmithKline. Press release. Available from URL: http://www.gsk.com/press_archive/mn_PR975485699.htm [Accessed 02 01 25]

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of RheumatologyBetanien HospitalSkienNorway
  2. 2.Centre for Rheumatic DiseasesNational HospitalOsloNorway

Personalised recommendations